Impact of the apolipoprotein E ε4 allele on early Parkinson's disease progression

Parkinsonism Relat Disord. 2021 Feb:83:66-70. doi: 10.1016/j.parkreldis.2021.01.004. Epub 2021 Jan 12.

Abstract

Objective: Emerging evidence shows that apolipoprotein E (APOE) ε4 exacerbates alpha-synuclein pathology. We aimed to investigate whether the APOE ε4 allele contributes to early Parkinson's disease (PD) progression.

Methods: This cohort study included 361 early PD patients who were classified as APOE ε4 carriers (n = 90) and noncarriers (n = 271). The patients underwent yearly motor and nonmotor assessments covering neuropsychiatric, sleep-related, and autonomic symptoms over 5 years of follow-up. Dopamine transporter (DAT) imaging was conducted at baseline and the 1-, 2-, and 4-year follow-up visits.

Results: The APOE ε4 carriers had steeper declines in the Montreal Cognitive Assessment score (p=0.005) and the semantic fluency test score (p=0.012) than the noncarriers. No significant between-group differences in the longitudinal changes in motor, other nonmotor, and DAT imaging variables were observed.

Conclusions: Our exploratory analyses show that only cognitive performance was negatively affected by the APOE ε4 allele in the progression of early PD. More specifically, this allele was associated with poorer performance in semantic verbal fluency among cognitive domains.

Keywords: Apolipoprotein; Dopamine transporter; Motor; Nonmotor; Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alleles
  • Apolipoprotein E4 / genetics*
  • Cognitive Dysfunction / diagnostic imaging
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / genetics*
  • Cognitive Dysfunction / physiopathology*
  • Disease Progression*
  • Dopamine Plasma Membrane Transport Proteins / pharmacokinetics
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / complications
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / genetics*
  • Parkinson Disease / physiopathology*
  • Positron-Emission Tomography

Substances

  • Apolipoprotein E4
  • Dopamine Plasma Membrane Transport Proteins